Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Larimar Therapeutics Inc

Healthcare US LRMR

3.465USD
-0.135(3.75%)

Last update at 2026-06-12T20:00:00Z

Day Range

3.433.73
LowHigh

52 Week Range

2.1813.68
LowHigh

Fundamentals

  • Previous Close 3.60
  • Market Cap470.86M
  • Volume1485138
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-50.54200M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.0

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -35.35500M -50.63600M -42.48200M -23.13200M -61.36800M
Minority interest - - - - -
Net income -34.18400M -50.31000M -42.32700M -23.13200M -61.36800M
Selling general administrative 12.28M 12.07M 11.40M 2.42M 13.19M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.32M 0.33M 0.15M 0.08M -
Ebit -36.84400M -50.79100M -42.95900M -23.21400M -61.61400M
Ebitda -36.52600M -50.46500M -42.80400M -23.13600M -61.35300M
Depreciation and amortization 0.32M 0.33M 0.15M 0.08M 0.26M
Non operating income net other 1.17M - 0.32M - -
Operating income -36.52600M -50.46500M -42.80400M -23.21400M -61.12200M
Other operating expenses 36.53M 50.47M 42.80M 23.21M 61.12M
Interest expense -0.31800M 0.33M 0.00000M -1.76600M 0.25M
Tax provision - - - - -
Interest income - - - 0.25M 0.25M
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.17100M -0.32600M -0.15500M -0.08200M -0.49200M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 36.53M 50.47M 42.80M 23.21M 61.12M
Cost of revenue - - - - -
Total other income expense net 1.17M -0.17100M 0.32M 0.08M -0.24600M
Discontinued operations - - - - -
Net income from continuing ops -35.35500M -50.63600M -42.48200M -23.13200M -
Net income applicable to common shares -35.35500M -50.63600M -42.48200M -23.13200M -11.19200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 95.94M 126.41M 78.67M 104.69M 5.20M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.38M 2.31M 2.11M 5.31M 0.42M
Total liab 14.21M 15.50M 14.25M 14.99M 5.89M
Total stockholder equity 81.72M 110.90M 64.41M 89.69M -0.69400M
Deferred long term liab - - - - -
Other current liab 7.39M 8.41M 6.59M 5.84M 2.26M
Common stock 0.04M 0.04M 0.02M 0.01M 0.00600M
Capital stock 0.04M 0.04M 0.02M 0.01M 0.00600M
Retained earnings -188.55400M -151.60500M -116.25000M -65.61400M -23.13200M
Other liab - - - - -
Good will - - - - -
Other assets - 1.98M 2.01M 1.76M 0.09M
Cash 26.75M 26.82M 70.10M 68.15M 1.01M
Cash and equivalents - - - - -
Total current liabilities 9.51M 10.71M 8.85M 8.99M 5.89M
Current deferred revenue - - - - -
Net debt -21.20300M -21.41700M -64.09500M -61.63100M -0.91200M
Short term debt 0.84M 0.61M 0.59M 0.52M 0.10M
Short long term debt - - - - -
Short long term debt total 5.55M 5.41M 6.00M 6.52M 0.10M
Other stockholder equity 270.15M 262.50M 180.65M 155.29M 22.40M
Property plant equipment - 0.83M 4.46M 4.98M 0.36M
Total current assets 90.17M 120.74M 72.20M 97.95M 4.75M
Long term investments - - - - -
Net tangible assets - 110.90M 64.41M 89.69M -0.69400M
Short term investments 60.04M 91.60M 0.00000M 24.49M 43.05M
Net receivables - - 0.21M 0.03M 0.16M
Long term debt - - - - 8.46M
Inventory - - -0.20800M -0.03200M 3.16M
Accounts payable 1.28M 1.69M 1.66M 2.63M 3.54M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.08M -0.03100M - 0.00100M 0.04M
Additional paid in capital - - - - -
Common stock total equity - 0.04M - 0.01M 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - -151.60500M - -65.61400M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.66M 1.98M 2.01M 1.76M 0.09M
Deferred long term asset charges - - - - -
Non current assets total 5.76M 5.67M 6.46M 6.73M 0.45M
Capital lease obligations 5.55M 5.41M 6.00M 6.52M 0.10M
Long term debt total - - - - 8.46M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -90.86000M 24.50M 17.09M -0.08300M -23.48600M
Change to liabilities 1.84M -0.97400M -3.28800M 2.63M 0.81M
Total cashflows from investing activities -90.96000M 24.17M 17.09M -0.08300M -0.09300M
Net borrowings - - - - -
Total cash from financing activities 75.26M 19.89M 93.59M 19.39M 66.91M
Change to operating activities 1.64M 3.72M 1.25M -2.40400M 0.64M
Net income -35.35500M -50.63600M -42.48200M -23.13200M -61.36800M
Change in cash -43.27200M 1.95M 68.48M -3.38700M 8.55M
Begin period cash flow 71.44M 69.49M 1.01M 4.40M 40.78M
End period cash flow 28.16M 71.44M 69.49M 1.01M 49.33M
Total cash from operating activities -27.56900M -42.10500M -42.19900M -22.69900M -51.48700M
Issuance of capital stock 75.26M 19.89M 75.59M 0.00000M -
Depreciation 0.32M 0.33M 0.15M 0.08M 0.26M
Other cashflows from investing activities - - 40.64M 26.03M -6.75900M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 75.26M - 75.59M 0.19M 67.22M
Other cashflows from financing activities -90.96000M 24.17M 18.00M 19.39M -0.31200M
Change to netincome 6.62M 5.46M 2.17M 0.13M 0.17M
Capital expenditures 0.10M 0.33M 0.06M 0.08M 0.11M
Change receivables - - - - -
Cash flows other operating -0.21900M - -1.98700M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -43.27200M - 68.48M - -
Change in working capital 1.67M 2.75M -2.04300M 0.23M 10.39M
Stock based compensation 6.62M 5.47M 2.16M 0.13M 9.63M
Other non cash items -0.82000M -0.01500M 0.01000M 22.27M -0.77200M
Free cash flow -27.66900M -42.43800M -42.26100M -22.78200M -51.59500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
LRMR
Larimar Therapeutics Inc		 -0.135 3.75% 3.46 - - - 5.43 -8.7534
NVO
Novo Nordisk A/S		 -0.08 0.18% 43.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.99 4.74% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.115 0.03% 444.93 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 0.66 0.11% 612.14 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics Inc

Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004

Key Executives

Name Title Year Born
Dr. Carole S. Ben-Maimon M.D. CEO, Pres & Director 1959
Mr. Michael Celano CPA Sec. & CFO 1959
Mr. John Berman VP of Fin. & Operations NA
Ms. Jennifer Spokes Johansson VP of Regulatory Affairs & Counsel NA
Dr. Nancy M. Ruiz Chief Medical Officer NA
Mr. Francis Michael Conway VP & Controller NA
Dr. Carole S. Ben-Maimon M.D. CEO, President & Director 1959
Mr. Michael Celano CPA Secretary & CFO 1959
Mr. John Berman Vice President of Finance & Administration NA
Ms. Jennifer Spokes Johansson Vice President of Legal & Compliance NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.